CRVS20250620C1
CRVS Jun 20 2025 1.00 Call (CRVS250620C00001000)
option OPRA

corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.